Candel Therapeutics, Inc.
News
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire NEEDHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...\n more…
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCandel Therapeutics just reported results for the second quarter of 2024.\nThe post CADL Stock Earnings: Candel Therapeutics Reported...\n more…
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Globe Newswire Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancerPresented positive topline overall survival data from the...\n more…
Paul Peter Tak Sells 22,528 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Zolmax Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CEO Paul Peter Tak sold 22,528 shares of the firm's stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of...\n more…
Seshu Tyagarajan Sells 14,851 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock
Zolmax Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 14,851 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of...\n more…